DGAP-News

CEVEC raises EUR 4.5 million in a financing round to commercialize its leading CAP(R) based technologies

DGAP-News: CEVEC Pharmaceuticals GmbH / Key word(s):
Financing/Miscellaneous
CEVEC raises EUR 4.5 million in a financing round to commercialize its
leading CAP(R) based technologies

22.07.2015 / 08:30

---------------------------------------------------------------------

CEVEC raises EUR 4.5 million in a financing round to commercialize its
leading CAP(R) based technologies

- New and existing investors participated in this financing round

- CEVEC is setting new industry standards in glyco-optimized protein and
gene therapy vector production with proprietary CAP(R)Go and CAP(R)GT
technologies

Cologne, Germany, July 22, 2015 - CEVEC Pharmaceuticals GmbH (CEVEC), the
expert in the production of tailor-made recombinant glycoproteins and gene
therapy vectors, today announced the successful completion of a financing
round of EUR 4.5 million. New investors included Investtodate GmbH, Frank
Ubags, CEO, and Nicole Faust, CSO of CEVEC. Existing investors also
participated in this financing. These included Peppermint VenturePartners
GmbH, Creathor Venture Management GmbH, NRW.Bank, KfW Bank, G.A.T. Holding
as well as a number of private individuals.

With the May 2015 introduction of the CAP(R)Go and CAP(R)GT production
systems, both based on its proprietary CAP(R) technology, CEVEC now focuses
on the fully scalable production of tailor-made glyco-optimized proteins
and gene therapy vectors. CEVEC will use the new capital to drive further
development of its unique CAP(R)Go and CAP(R)GT platforms, thus creating
new industry standards for the manufacturing of recombinant glycoproteins
as well as viral vectors for gene therapy applications.

CEVEC's CAP(R)Go system comprises a comprehensive panel of glyco-optimized
human suspension cell lines that differ in their glycosylation capabilities
and allow for the recombinant production of a variety of complexly
glycosylated proteins such as cytokines, ion channels, virus envelope
proteins, coagulation factors or other plasma proteins to name just a few.
Most recently, the company published data on glyco-optimized recombinant
human alkaline phosphatase and C1 esterase inhibitor, which both showed
excellent pharmacokinetic properties in preclinical studies compared to
existing recombinant or serum-derived molecules including significantly
prolonged serum-half-lives.

With its CAP(R)GT cell lines, CEVEC provides a novel platform for the